Bevacizumab

nork Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Argitaratua 2010

Trastuzumab

nork Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

nork Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Argitaratua 2009

Concise Drug Review: Azacitidine and Decitabine

nork Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2013

Inhibitors of mTOR

nork Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Argitaratua 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

nork Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

nork Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

nork Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

nork Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

nork Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2013

Lapatinib for Advanced or Metastatic Breast Cancer

nork Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2012

Concise Drug Review: Pazopanib and Axitinib

nork van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

nork van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Argitaratua 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

nork Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Argitaratua izan da Clin Pharmacokinet (2017)

Treatment Individualization in Colorectal Cancer

nork van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Argitaratua izan da Curr Colorectal Cancer Rep (2015)

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

nork van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Argitaratua izan da Oncologist (2017)

Letter to the Editor Regarding “A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer” by Y...

nork Mooiman, Kim D., Goey, Andrew K.L., Meijerman, Irma, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua 2012

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

nork Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Argitaratua 2012

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

nork Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Argitaratua 2011

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

nork van Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
Argitaratua izan da Oncologist (2016)